Shares in Johnson & Johnson (NYSE:JNJ) fell this week after the company missed the consensus top-line forecasts but pulled off earnings beats for both the 4th quarter and 2016. Pharmaceutical sales grew 6.5% for the full-year to $33.5 billion, with an operational increase of 7.4%. Domestic sales climbed nearly 10% and international sales increased 1.8%. New Brunswick, […]
MassDevice Earnings Roundup
Biogen beats Q4 earnings, misses on full-year rev forecast
Shares in Biogen (NSDQ:BIIB) rose this week after the biopharmaceutical company met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower than analysts expected. The Cambridge, Mass.-based company posted profits of $649.2 million, or $2.99 per share, on sales of $2.87 billion for the 3 months ended Dec. […]
Mylan’s Q3 misses on $465 million Medicaid settlement
Shares in Mylan (NDSQ:MYL) rose slightly today after the pharmaceutical giant missed expectations on Wall Street with its 3rd-quarter results. The Canonsburg, Pa.-based company posted a net loss of -$119.8 million, or -23¢ per share, on sales of $3.06 billion for the 3 months ended Sept. 30, for a bottom-line slide of -3% on sales growth of 14.2% […]
Clearside tops Q3 estimates, posts license revenue
Shares in Clearside Biomedical (NSDQ:CLSD) rose today after the biopharmaceutical company met expectations on Wall Street with its 3rd quarter results. The Alpharetta, Ga.-based company posted losses of -$5.6 million, or -28¢ per share, on sales of $5,000 for the 3 months ended Sept. 30. This is the 1st quarter that Clearside has reported revenue. Adjusted to exclude […]
Ocular Therapeutix plans FDA re-submission for Dextenza by end of year, earnings
Shares in Ocular Therapeutix (NSDQ:OCUL) surged this morning after the biopharmaceutical company met expectations on Wall Street with its 3rd-quarter results and announced it will re-submit its new drug application to the FDA for Dextenza, its post-surgical ocular pain reliever, by the end of the year. In July, the FDA denied approval for Ocular’s hydrogel plug designed […]
pSivida misses Q1 estimates, profits slide 47%
Shares in pSivida (NSDQ:PSDV) fell 6% today after the company missed expectations on Wall Street with its fiscal 1st-quarter results*. The Watertown, Mass.-based company posted losses of -$7.2 million, or -21¢ per share, on sales of $277,000 for the 3 months ended Sept. 30, for a bottom-line loss of -47% on a -41% sales decline, compared […]
Catalent tops Q1 estimates, profits fall 61%
Shares in Catalent (NYSE:CTLT) rose yesterday after the drug-delivery company met expectations on Wall Street with its fiscal 1st-quarter results. The Somerset, N.J.-based company posted profits of $4.6 million, or 4¢ per share, on sales of $442.2 million for the 3 months ended Sept. 30, for a bottom-line slide of -60.7% on sales growth of 4.5% compared with […]
Flamel Technologies tops Q3 revenue, EPS estimate
Shares in Flamel Technologies (NSDQ:FLML) rose today after the pharmaceutical company met expectations on Wall Street with its 3rd quarter results. The Venissieux, France-based company posted a loss of -$22.3 million on sales of $32.1 million for the 3 months ended Sept. 30, for bottom-line growth of 20% despite a sales loss of 32% compared with the […]
Regeneron boosts profits, misses revenue in Q3
Shares in Regeneron (NSDQ:REGN) gained today after the biopharmaceutical company crushed earnings expectations on Wall Street with its 3rd-quarter results. The Tarrytown, N.Y.-based company posted profits of $264.8 million, or $2.27 per share, on sales of $1.22 billion for the 3 months ended Sept. 30, for bottom-line growth of 26% on sales growth of 7.3% compared with the […]
Pulmatrix reports Q3 loss, revenue down 91%
Shares in Pulmatrix (NSDQ:PULM) remained steady after the biopharmaceutical company released its 3rd quarter results. The Lexington, Mass.-based company reeled in its losses by -35% to -$3.2 million compared to Q3 last year. Revenue fell -91% compared with the same period last year to $61,000 for the 3 months ended Sept. 30. Losses per share were -21¢. Pulmatrix cited the conclusion of […]